Newleos Announces $15.5 Million NIH Grant and Receipt of FDA Fast Track Designation for NTX-2001 to Treat Substance Use Disorders | Morningstar

Newleos also announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to NTX-2001 for the treatment of AUD. The FDA’s Fast Track process…

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.morningstar.com)